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Abstract: In patients with Duchenne muscular dystrophy (DMD), death secondary to cardiac or
respiratory failure typically occurs in the second or third decade without treatment. Although cardiac
dysfunction is treated with standard heart-failure strategies, it remains insufficient in DMD children.
The purpose of this study was to evaluate the efficiency of cardiac medication and noninvasive
ventilator support in DMD cardiomyopathy children with analyzing echocardiographic data.
Forty-eight DMD children patients were included and divided into 2 groups by left ventricular
(LV) ejection fraction (EF) at the time of initial treatment. Group 1: LV EF ≥ 45% and Group 2:
LV EF < 45%. p-values were calculated using a Linear mixed model to estimate the association between
cardiac medications and echocardiographic measurements. Before and after cardiac medications,
the change values were significantly different in interventricular septal thickness at end diastole
(IVSd), interventricular septal thickness at end systole (IVSs), left ventricular internal diameter end
systole (LVIDs), left ventricular posterior wall thickness end diastole (LVPWd), ejection fraction
(EF), fractional shortening (FS), deceleration time (DT), DT slope, Lat A’ and Lat E/E’ (p < 0.05).
Group 2 patients revealed to take more kinds of cardiac medications than Group 1 (p < 0.05) including
ACEIs, beta-blocker, and inotropics, then LV EF was better preserved in Group 2 than Group 1. It is
certainly helpful to take individualized medical combination therapy including inotropic agents for
cardiomyopathy in DMD children patients with EF < 45%.
Keywords: Duchenne muscular dystrophy; children; cardiomyopathy; heart failure;
echocardiography; medication
1. Introduction
Duchenne muscular dystrophy (DMD), an X-linked disorder due to lack of dystrophin,
is characterized by progressive muscle weakness and myocardial dysfunction [1]. DMD is typically
diagnosed between the ages of 3 and 7 years and is characterized by progressive skeletal muscle
weakness with loss of ambulation between the ages of 7 and 13 years [2]. Without treatment,
death secondary to cardiac or respiratory failure typically occurs in the second or third decade in
DMD. Respiratory care of DMD patients has improved as a result of the development of supportive
equipment and techniques [3]. Advances in the respiratory care of patients with DMD have improved
their prognosis. Nocturnal home ventilators and mechanically assisted coughing lead to improved
survival of patients with DMD [4]. The American Thoracic Society has published a statement regarding
the respiratory care of patients with DMD, including evaluation and management (i.e., respiratory
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muscle training, mechanical ventilation, corticosteroids, and end of-life care) [5]. These improvements
in respiratory care make cardiac complications the leading cause of death in patients with DMD [6–10].
Consequently, dilated cardiomyopathy and depressed cardiac function are increasing as the major
cause of death.
Evidence of myocardial involvement begins with minor electrocardiographic abnormalities [11].
Then cardiac involvement evolves to cardiomyopathy with dilatation of the cardiac chambers
and depression of left ventricular ejection fraction due to widespread fibrosis. Progression of
cardiomyopathy is the major cause of mortality. Cardiomyopathy can occur at any age but often occurs
around 14–15 years [12,13].
Although cardiac dysfunction is treated with standard heart-failure strategies, it remains
insufficient in DMD children. The treatment paradigms have been individually based and relied on
evidence acquired from other patient populations [2]. There are some reports that support the efficacy
of angiotensin-converting enzyme inhibitors (ACEIs) on left ventricular function and mortality of
DMD patients [11]. In addition to ACEIs, angiotensin receptor blockers, beta-blockers, or aldosterone
antagonists are often used for management of Duchenne cardiomyopathy and show improvements in
cardiac function. Oral corticosteroid treatment can delay the onset of Duchenne cardiomyopathy [14].
However, except for ACEIs, there are no reports on the efficacy of other medications.
Baseline assessment of cardiac function is needed for patients with DMD at diagnosis, and annual
cardiac assessment is recommended for patients with DMD older than 10 years. Poor treatment
outcomes have been noticed in patients with DMD who fail to see a cardiologist after the onset of
clinical symptoms of heart failure [2,11–13].
In our hospital, we treated DMD cardiomyopathy patients with cardiac medication and respiratory
care. After the start of treatment, we could see the improvement of patients’ early symptoms of heart
failure like poor oral intake, night sweat, chest discomfort, fatigue, palpitation or sleep disturbance etc.
Based on this, the purpose of this study was to evaluate the efficiency of cardiac medication in DMD
cardiomyopathy patients with analyzing echocardiographic data to preserve the cardiac function.
2. Experimental Section
2.1. Patient Enrollment and Data Measurement
We collected sixty-seven DMD cardiomyopathy patient’s data in Gangnam Severance Hospital,
Korea, from January 2014 to December 2018. Among them, forty-eight patients were enrolled in this
study, twelve patients were excluded due to the lack of data and seven patients were excluded due to
the loss of follow up (Figure 1).
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Figure 1. Sixty-seven DMD (Duchenne muscular dystrophy) cardiomyopathy patients’ data were
collected. Nineteen patients were excluded due to the lack of data or loss of follow up. Forty-eight
DMD patients were divided into 2 groups of left ventricle ejection fraction (LVEF) at initial treatment
over 45% (Group 1) and under 45% (Group 2). N; number.
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We retrospectively reviewed the medical record of their cardiac medications (Beta-blocker,
ACE inhibitor, Diuretics, Inotropics, Aspirin etc.), echocardiographic data, demographic data and
non-invasive ventilator apply time per day.
For each patient diagnosed with DMD cardiomyopathy, we performed echocardiography at least
one time before treatment and at least one time after treatment. We acquired conventional and advanced
echocardiographic data for analyzing myocardial function. All conventional echocardiographic
measurements and advanced myocardial imaging studies were obtained in all enrolled patients with
DMD using a Siemens model ACUSON SC2000 (Siemens Medical Solutions USA, Inc., Mountain View,
California, USA). Echocardiographic examinations were conducted according to the recommendations
of the American Society of Echocardiography, and based on the guidelines and Standards for
Performance of a Pediatric Echocardiogram: A Report from the Task Force of the Pediatric Council
of the American Society of Echocardiography [15]. The parameters included in this study are listed:
Interventricular septal thickness at end diastole (IVSd), Interventricular septal thickness at end systole
(IVSs), Left ventricular internal diameter end diastole (LVIDd), Left ventricular internal diameter
end systole (LVIDs), Left ventricular posterior wall thickness end diastole (LVPWd), Left ventricular
posterior wall thickness end systole (LVPWs), End-diastolic volume (EDV), End-systolic volume (ESV),
Ejection fraction (EF), Stroke volume (SV) and Fractional shortening (FS). Doppler measurement data
included of mitral E, mitral A, E/A, Deceleration time (DT), DT slope, tissue Doppler Septal (Sep) E’,
Sep A’, Sep S’, Sep E/E’, Lateral (Lat) E’, Lat A’, Lat S’ and Lat E/E’.
2.2. Study Design and Statistical Analysis
The change values of echocardiographic functional measurements were calculated subtracting the
initial echocardiographic data from the last echocardiographic data and we analyzed these change
values with linear mixed model. Then, we evaluated the relationship between significant change
values and cardiac medication with respiratory care by linear regression. To analyze the treatment
outcome between the two groups which is divided based upon LV EF (left ventricular ejection fraction),
we evaluated relationship between the change values of echocardiographic parameters and cardiac
medication and respiratory care with linear mixed interaction test. The p values were set using a linear
mixed model to evaluate the change of each echocardiographic data with cardiac medication over
time, and estimate the interaction between the change values of EF in each group. For this analysis,
variables with p < 0.05 on the unadjusted analysis were entered.
Statistical analyses were performed using SAS ver. 9.3 (SAS Inc., Cary, NC, USA). The p-values
less than 0.05 were considered statistically significant.
2.3. Ethics Statement
This study was approved by the Yonsei University College of Medicine Institutional Review Board
and the Research Ethics Committee of Severance Hospital (study approval number: 2020-0697-001).
All research was performed in accordance with relevant guidelines and regulations. The requirement
for written informed consent was waived by the Institutional Review Board due to the retrospective
study design.
3. Results
We reviewed 48 DMD patients and divided into two groups based on their ejection fraction
at initial treatment. The demographic characteristics of patients with DMD are shown in Table 1.
All patients were male. Age at first medication in Group 2 (17.11 ± 2.30 years) was older than in Group
1 (14.3 ± 5.77 years) (p < 0.05). For medications, Group 2 (4.6 ± 1.58) presented to take more kinds of
medications than Group 1 (3.07 ± 1.26) (p < 0.05). But onset age of ACE inhibitor was similar between
two groups. For height and weight of the patients, Group 1 (143.663 ± 4.606 cm) was smaller than
Group 2 (158.556 ± 1.7827 cm) (p < 0.05) and Group 2 (45.7167 ± 2.822 kg) weighed more than Group 1
(34.7067± 2.5223 kg) (p < 0.05). Ventilator apply time per day and initial end-tidal CO2 (EtCO2) was
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not significantly different between the two groups. Initial EtCO2 was not statistically different between
patients treated with ventilator and patients without ventilator. The follow-up duration was similar
between two groups from 6 months to 4 years. They have been in treatment at least two years, and at
most 6 years. As the time of their first clinic visit is individually different, the start of treatment is
various for each patient.
Table 1. Demographic characteristics of patients with Duchenne muscular dystrophy.
Characteristics Mean ± SD MinimumValue
Maximum
Value p-Value
Age at first medication (year)
(N = 48) 15.35 ± 4.93 2 22 0.022
Group 1 (N = 30) 14.30 ± 5.77 2 21 -
Group 2 (N = 18) 17.11 ± 2.30 14 22 -
Age of the ACEi onset (year)
(N = 37) 16.03 ± 3.97 2 22 0.257
Group 1 (N = 22) 15.41 ± 0.10 2 21 -
Group 2 (N = 15) 16.93 ± 0.64 14 22 -
Height (cm) (N = 48) 149.25 ± 21.60 75.2 176 0.005
Group 1 (N = 30) 143.67 ± 4.61 75.2 176 -
Group 2 (N = 18) 158.56 ± 1.78 145 170 -
Weight (kg) (N = 48) 38.84 ± 14.09 9.4 65.55 0.007
Group 1 (N = 30) 34.71 ± 2.52 9.4 65.55 -
Group 2 (N = 18) 45.72 ± 2.82 22 65 -
Number of medication
(N = 48) 3.65 ± 1.56 0 7 0.001
Group 1 (N = 30) 3.07 ± 1.26 1 6 -
Group 2 (N = 18) 4.60 ± 1.58 0 7 -
Ventilator apply time per day
(hour) (N = 48) 4.42 ± 4.99 0 19 0.977
Group 1 (N = 30) 4.43 ± 4.94 0 19 -
Group 2 (N = 18) 4.38 ± 5.23 0 17 -
Initial EtCO2 (N = 38) 36.76 ± 6.29 24 53 0.611
Group 1 (N = 24) 37.17 ± 6.40 24 53 -
Group 2 (N = 14) 36.07 ± 6.27 25 51 -
Initial EtCO2 (N = 38) 36.76 ± 6.29 24 53 0.09
Ventilator (N = 24) 38.08 ± 6.84 24 53 -
Non-ventilator (N = 14) 34.05 ± 4.59 25 51 -
Duration of follow up (year)
(N = 48) 1.57 ± 0.63 0.5 3.75 0.14
Group 1 (N = 30) 1.66 ± 0.72 0.5 3.75 -
Group 2 (N = 18) 1.41 ± 0.42 1 2.33 -
N: number; Group 1: Ejection fraction at initial treatment over 45%; Group 2: Ejection fraction at initial treatment
under 45%; EF: Ejection fraction; EtCO2: End-tidal CO2; ACEi: Angiotensin-converting enzyme inhibitor.
The change values of systolic and diastolic echocardiographic data and the mean values of
echocardiography which were taken before and after treatment are shown in Table 2. The change
values were significantly different in IVSd, IVSs, LVIDs, LVPWd, EF, FS, DT, DT slope, Lat A’ and
Lat E/E’ (p < 0.05). For the detail, IVSd became thinner by 0.07 cm and IVSs by 0.06 cm per year.
LVPWd became thinner by 0.05 cm per year. LVIDs enlarged 0.13 cm per year. LV EF decreased 2.68%,
FS 1.72% per year. With the Doppler data, DT decreased 7.3 ms, DT slope increased 0.6 m/s2 per year.
Lat A’ became shorter by 0.41 cm/s, Lateral E/E’ changed by 0.57 per year (Table 2).
We assessed the impact of cardiac medication on these echocardiographic data with linear
regression analysis (Table 3). Most of the parameters are not statistically associated with the medications,
except the relevance between IVSd and diuretics. The use of diuretics accelerated the thinning of IVSd
by 0.06 cm per year (p < 0.05).
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Table 2. The change values of echocardiographic data over time and the mean values of echocardiography before and after treatment.
Variable
Treatment Linear Mixed Model
Variable
Treatment Linear Mixed Model
Before (S.E) After (S.E) B (S.E) p-Value Before (S.E) After (S.E) B (S.E) p-Value
IVSd (cm) 0.720 (0.194) 0.588 (0.118) −0.069 (0.014) <0.0001 Mitral E(cm/s) 80.511 (19.320) 83.222 (15.750) 1.113 (1.329) 0.4065
IVSs (cm) 0.938 (0.221) 0.805 (0.130) −0.059 (0.017) 0.0008 Mitral A(cm/s) 46.956 (13.270) 51.689 (14.550) 1.446 (1.383) 0.3012
LVIDd (cm) 4.460 (0.988) 4.572 (1.018) 0.086 (0.046) 0.0688 E/A 1.825 (0.572) 1.685 (0.434) −0.044 (0.052) 0.3999
LVIDs (cm) 3.400 (1.148) 3.571 (1.115) 0.128 (0.040) 0.0027 DT (msec) 134.50 (29.750) 119.860(23.150) −7.287 (3.186) 0.0267
LVPWd (cm) 0.660 (0.152) 0.586 (0.120) −0.045 (0.013) 0.0008 Dtslope (m/s2) 6.214 (1.840) 7.185 (1.902) 0.642 (0.233) 0.0083
LVPWs(cm) 0.919 (0.159) 0.891 (0.158) −0.017 (0.017) 0.3388 Sep E’ (cm/s) 8.911 (2.357) 8.783 (2.422) −0.071 (0.171) 0.6788
EDV (mL) 104.285(55.960) 93.633 (59.270) −0.017 (0.017) 0.3388 Sep A’ (cm/s) 4.444 (1.267) 4.278 (1.549) −0.259 (0.148) 0.0876
ESV (mL) 63.476 (45.000) 55.326 (45.750) −8.749 (4.576) 0.0624 Sep S’ (cm/s) 5.023 (1.255) 5.389 (1.360) 0.114 (0.160) 0.4802
EF (%) 49.676 (15.344) 46.217 (14.120) −2.680 (0.694) 0.0003 Sep E/E’ 9.310 (2.483) 10.432 (4.032) 0.549 (0.300) 0.0737
SV (mL) 40.796 (13.436) 38.297 (16.540) 1.355 (2.472) 0.5866 Lat E’ (cm/s) 11.651 (3.800) 10.823 (3.689) −0.420 (0.325) 0.2033
FS (%) 25.787 (8.635) 23.480 (8.000) −1.722 (0.496) 0.0011 Lat A’(cm/s) 5.497 (1.604) 5.000 (1.765) −0.413 (0.188) 0.0334
Lat S’(cm/s) 4.283 (1.647) 5.333 (2.746) 0.369 (0.466) 0.4343
Lat E/E’ 6.987 (1.887) 8.401 (2.426) 0.565 (0.254) 0.0318
S.E: Standard error; IVSd: Interventricular septal end diastole; IVSs: Interventricular septal end systole; LVIDd: Left ventricular internal diameter end diastole; LVIDs: Left ventricular
internal diameter end systole; LVPWd: Left ventricular posterior wall end diastole; LVPWs: Left ventricular posterior wall end systole; EDV: End-diastolic volume; ESV, End-systolic
volume; EF: Ejection fraction; SV: Stroke volume; FS: Fractional shortening; DT: Deceleration time; E: peak early inflow velocity; A: peak late inflow velocity; Sep: septal; Lat: lateral, E’:
peak early diastolic velocity; A’: peak late diastolic velocity; S’: peak systolic velocity.
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Table 3. Linear regression analysis of the effect of cardiac medication and respiratory care on
echocardiographic measurements.
IVSd (cm) IVSs (cm) LVIDs (cm)
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker 0.044 (0.039) 0.2696 0.021 (0.048) 0.6634 −0.029 (0.117) 0.3696
ACE inhibitor 0.012 (0.031) 0.7021 0.007 (0.038) 0.8646 −0.019 (0.094) 0.8443
Diuretic −0.063 (0.026) 0.0213 −0.055 (0.033) 0.0951 0.108 (0.080) 0.1824
Aspirin 0.022 (0.028) 0.428 0.048 (0.033) 0.1605 −0.056 (0.082) 0.4996
Inotropic 0.018 (0.029) 0.543 0.051 (0.034) 0.1445 −0.032 (0.084) 0.7107




−0.001 (0.003) 0.7593 −0.001 (0.004) 0.8939 0.012 (0.009) 0.2057
LVPWd (cm) EF (%) FS (%)
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker 0.033 (0.036) 0.3696 −3.483 (1.941) 0.0793 −0.266 (1.45) 0.8552
ACE inhibitor −0.005 (0.029) 0.8572 −1.312 (1.596) 0.4154 −0.268 (1.095) 0.8079
Diuretic −0.018 (0.025) 0.4877 −2.152 (1.358) 0.12 −1.368 (0.985) 0.1714
Aspirin 0.012 (0.026) 0.6512 0.071 (1.421) 0.9605 1.326 (0.985) 0.185
Inotropic 0.003 (0.026) 0.9241 −0.706 (1.439) 0.6259 0.239 (1.009) 0.814




−0.001 (0.003) 0.6441 −0.087 (0.160) 0.5889 −0.097 (0.109) 0.3789
DT (ms) DT slope (m/s2) Lat A’ (cm/s)
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker 1.720 (9.293) 0.854 0.374 (0.692) 0.5914 0.850 (0.550) 0.1297
ACE inhibitor 5.981 (7.322) 0.4182 −0.327 (0.535) 0.5436 −0.054 (0.401) 0.8929
Diuretic −2.333 (6.535) 0.7227 −0.206 (0.461) 0.6564 −0.494 (0.367) 0.1855
Aspirin −10.233 (6.233) 0.1075 0.405 (0.466) 0.3896 0.243 (0.383) 0.5293
Inotropic −8.976 (6.559) 0.1778 −0.039 (0.481) 0.9361 0.579 (0.382) 0.1368




0.557 (0.736) 0.4533 −0.060 (0.053) 0.2692 −0.015 (0.044) 0.7329
Lat E/E’
B (S.E) p-Value
Beta-blocker −0.138 (0.714) 0.8478
ACE inhibitor 0.260 (0.537) 0.6308
Diuretic −0.204 (0.535) 0.7049
Aspirin 0.282 (0.522) 0.5918
Inotropic 0.074 (0.529) 0.8891





S.E: standard error; ACE inhibitor: angiotensin-converting enzyme inhibitors; IVSd: interventricular septal end
diastole; IVSs: interventricular septal end systole; LVIDs: left ventricular internal diameter end systole; LVPWd: left
ventricular posterior wall end diastole; EF: ejection fraction; FS: fractional shortening; DT: deceleration time; A’:
peak late diastolic velocity; E: peak early inflow velocity; E’: peak early diastolic velocity.
The change values of the EF between Group 1 and Group 2 are shown in Table 4. In Group 1,
EF decreased with 3.62% per year of statistical significance, while in Group 2, EF became decreased
with 0.58% per year (p < 0.05). With the result in Table 1, we compared medications in two groups
to evaluate which medication related LV EF most. Obviously, inotropic agents were more taken in
Group 2 patients (Table 5).
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Table 4. The change value of the ejection fraction between Group 1 and Group 2 with linear mixed
model analysis.
Subgroup EF (%) EF2 (%) B (Standard Error) p-Value
Group 1 59.297 ± 8.407 53.594 ± 9.743 −3.615 (0.798)
0.0486Group 2 33.923 ± 11.547 33.642 ± 9.736 −0.582 (1.266)
Group 1: ejection fraction at initial treatment over 45%; Group 2: ejection fraction at initial treatment under 45%;
EF: ejection fraction at the initial treatment; EF2: ejection fraction at the last treatment.
Table 5. Medication comparison between two groups with chi-square test.
Medication WhetherTaking Total (N = 48) Group 1 (N = 30) Group 2 (N = 18) p-Value
Beta-blocker Yes 41 27 14 0.4002
No 7 3 4
ACE inhibitor Yes 37 22 15 0.4991
No 11 8 3
Diuretic Yes 26 14 12 0.1782
No 22 16 6
Aspirin Yes 25 13 12 0.1172
No 23 17 6
Inotropic Yes 28 12 16 0.0009
No 20 18 2
To compare the effect of treatment, we analyzed relationship between the change values of
echocardiographic data and cardiac medication & respiratory care in each group (Table 6). Taking ACE
inhibitor in Group 2 was related to increase in IVSd, IVSs and LVPWd (p < 0.05), and also related to
decrease in Sep S’ and Lat E/E’ and increase in Sep A’ (p < 0.05). Taking inotropic in Group 2 was related
to increase in Sep E’ and Lat A’ (p < 0.05). Taking inotropic agents in Group 1 was related to increase in
IVSs and decrease in DT (p < 0.05). The effect of these two medications, ACE inhibitor and inotropic
agent in each group was demonstrated as a graph by Forest plot (Figure 2). Taking beta-blocker in
Group 2 was related to decrease in EDV, EF, SV and FS (p < 0.05). Taking aspirin in Group 1 related to
increase in IVSs and taking aspirin in Group 2 was related to decrease in SV (p < 0.05). Taking diuretics
in Group 2 was related to decrease in Sep E/E’ (p < 0.05). Ventilator use in Group 2 was related to
increase in mitral E (p < 0.05) (Table 6).
Children 2020, 7, 249 8 of 16
Table 6. Linear mixed model analysis of the effect of cardiac medication and respiratory care on echocardiographic measurements in each group.
IVSd (cm) in Group 1 IVSd (cm) in Group 2
p-Value *
IVSs (cm) in Group 1 IVSs (cm) in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker 0.052 (0.043) 0.2415 0.027 (0.067) 0.6888 0.9102 0.039 (0.058) 0.5047 −0.035 (0.080) 0.6786 0.9102
ACE
inhibitor −0.001 (0.030) 0.9616 0.191 (0.059) 0.0039 0.0408 −0.026 (0.030) 0.5196 0.239 (0.088) 0.0127 0.0408
Diuretic −0.055 (0.020) 0.0541 −0.115 (0.090) 0.2295 0.4655 −0.069 (0.030) 0.0654 0.040 (0.116) 0.7351 0.4655
Aspirin 0.023 (0.028) 0.4142 0.006 (0.063) 0.9254 0.8844 0.074 (0.034) 0.0384 0.018 (0.076) 0.8178 0.8844
Inotropic 0.023 (0.027) 0.4009 0.136 (0.094) 0.1635 0.3341 0.072 (0.033) 0.0361 −0.015 (0.130) 0.9092 0.3341
Ventilator 0.008 (0.029) 0.7954 −0.017 (0.050) 0.7515 0.6758 0.017 (0.038) 0.6574 −0.070 (0.063) 0.2769 0.6758
LVIDd (cm) in Group 1 LVIDd (cm) in Group 2
p-Value *
LVIDs (cm) in Group 1 LVIDs (cm) in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker −0.162 (0.160) 0.3216 −0.384 (0.260) 0.1550 0.5472 −0.129 (0.140) 0.3755 −0.042 (0.240) 0.8663 0.6953
ACE
inhibitor −0.107 (0.100) 0.3284 −0.219 (0.340) 0.5380 0.5986 −0.093 (0.097) 0.3476 −0.168 (0.310) 0.5938 0.5845
Diuretic 0.107 (0.105) 0.3168 0.512 (0.408) 0.2233 0.47944 0.120 (0.092) 0.2003 0.705 (0.382) 0.0788 0.3563
Aspirin 0.086 (0.105) 0.4167 −0.153 (0.230) 0.5265 0.4814 0.106 (0.093) 0.2637 −0.001 (0.226) 0.9991 0.6239
Inotropic −0.039 (0.100) 0.7018 −0.513 (0.460) 0.2801 0.2265 −0.031 (0.080) 0.7260 −0.270 (0.422) 0.5283 0.3862
Ventilator −0.062 (0.100) 0.5681 −0.131 (0.220) 0.5715 0.6733 0.008 (0.095) 0.9353 −0.188 (0.200) 0.3765 0.3211
LVPWd (cm) in Group 1 LVPWd (cm) in Group 2
p-Value *
LVPWs (cm) in Group 1 LVPWs (cm) in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker 0.060 (0.048) 0.2199 −0.040 (0.059) 0.5033 0.3869 0.034 (0.069) 0.6306 0.008 (0.042) 0.8468 0.9761
ACE
inhibitor −0.023 (0.030) 0.4828 0.129 (0.058) 0.0378 0.036 −0.017 (0.040) 0.7084 0.033 (0.055) 0.5526 0.5405
Diuretic −0.018 (0.030) 0.5703 −0.012 (0.070) 0.8788 0.8898 −0.024 (0.040) 0.5986 −0.121 (0.060) 0.0576 0.7605
Aspirin 0.004 (0.031) 0.8876 −0.022 (0.050) 0.6709 0.8216 −0.009 (0.040) 0.8440 −0.220 (0.040) 0.5888 0.8872
Inotropic −0.006 (0.030) 0.8313 0.081 (0.086) 0.3590 0.2695 −0.049 (0.040) 0.2402 0.043 (0.066) 0.5252 0.4079
Ventilator −0.018 (0.030) 0.5751 −0.014 (0.040) 0.7467 0.9996 −0.036 (0.040) 0.4186 0.028 (0.039) 0.4879 0.3906
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EDV (mL) in Group 1 EDV (mL) in Group 2
p-Value *
ESV (mL) in Group 1 ESV (mL) in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker −42.170 (27.500) 0.1369 −61.310 (24.200) 0.0215 0.4629 −21.263 (16.700) 0.2141 −28.740 (21.500) 0.1995 0.7485
ACE
inhibitor −19.070 (12.100) 0.1280 −40.350 (31.300) 0.2146 0.6434 −11.580 (6.450) 0.0837 −36.170 (23.100) 0.1363 0.3155
Diuretic 13.180 (11.260) 0.2518 1.605 (30.909) 0.9592 0.4663 8.648 (5.997) 0.1608 6.707 (24.460) 0.7873 0.4025
Aspirin 2.255 (10.940) 0.8383 −23.740 (22.520) 0.3064 0.5379 4.827 (5.882) 0.4191 −4.860 (20.400) 0.8146 0.8402
Inotropic −13.130 (9.160) 0.1631 −85.240 (45.610) 0.0790 0.0813 −6.720 (4.905) 0.1820 −665.800(36.400) 0.0887 0.0554
Ventilator 1.167 (12.230) 0.9247 20.963 (23.580) 0.3865 0.0898 2.157 (6.700) 0.7499 25.950 (16.960) 0.1443 0.0100
EF (%) in Group 1 EF (%) in Group 2
p-Value *
SV (mL) in Group 1 SV (mL) in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker 0.276 (2.549) 0.9144 −7.623 (2.700) 0.0099 0.2237 −20.260 (12.120) 0.1062 −42.860 (6.470) <0.0001 0.0698
ACE
inhibitor 0.019 (1.707) 0.9912 0.152 (4.070) 0.9706 0.7009 −7.705 (6.000) 0.2100 −1.719 (22.800) 0.9409 0.2604
Diuretic −0.616 (1.650) 0.7120 −2.774 (4.590) 0.5525 0.6105 3.860 (5.584) 0.4953 −4.708 (11.000) 0.675 0.2091
Aspirin −2.350 (1.622) 0.1556 −4.186 (2.870) 0.1588 0.6596 −3.471 (5.320) 0.5201 −22.220 (6.940) 0.0053 0.0108
Inotropic 0.171 (1.528) 0.9113 −4.287 (5.233) 0.4215 0.7733 −6.525 (4.630) 0.1709 −17.160 (33.400) 0.6145 0.8761
Ventilator −0.875 (1.590) 0.5861 4.269 (2.675) 0.1247 0.1180 −1.64 (5.692) 0.7752 −13.490 (14.000) 0.3507 0.4352
FS (%) in Group 1 FS (%) in Group 2
p-Value *
Mitral E (m/s) in Group 1 Mitral E (m/s) in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker −0.078 (1.870) 0.9672 −3.005 (1.310) 0.0327 0.6099 5.015 (4.460) 0.2692 4.036 (5.141) 0.4412 0.4521
ACE
inhibitor 0.223 (1.332) 0.8681 −0.001 (1.600) 0.9994 0.8995 −0.032 (3.140) 0.992 −3.590 (6.685) 0.5969 0.6398
Diuretic −0.911 (1.260) 0.4766 −1.529 (1.970) 0.4475 0.8784 −2.417 (3.050) 0.4339 0.025 (7.997) 0.9975 0.9696
Aspirin −1.430 (1.270) 0.2682 −0.122 (1.420) 0.9326 0.9436 −3.073 (2.967) 0.3078 4.849 (4.763) 0.3202 0.2114
Inotropic 0.222 (1.233) 0.8584 −2.612 (1.927) 0.1892 0.8177 −5.527 (2.750) 0.0534 −0.519 (9.440) 0.9567 0.585
Ventilator −0.163 (1.250) 0.8970 2.180 (1.140) 0.0689 0.2167 −3.903 (2.915) 0.1898 9.385 (4.194) 0.0362 0.0296
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Mitral A (cm/s) in Group 1 Mitral A (cm/s) in Group 2
p-Value *
E/A in Group 1 E/A in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker −2.774 (4.940) 0.5787 1.937 (8.074) 0.8127 0.5846 0.142 (0.155) 0.3648 −0.543 (0.380) 0.1704 0.0635
ACE
inhibitor −4.999 (3.090) 0.1161 −12.750 (10.230) 0.2264 0.3582 0.160 (0.103) 0.1288 0.292 (0.459) 0.5315 0.6024
Diuretic −3.093 (3.210) 0.3433 −11.560 (9.149) 0.2199 0.0809 0.093 (0.105) 0.3827 0.548 (0.388) 0.1720 0.187
Aspirin −2.403 (3.070) 0.4401 5.676 (6.951) 0.4234 0.1879 −0.052 (0.104) 0.6208 −0.464 (0.280) 0.1183 0.0807
Inotropic −2.625 (3.000) 0.3880 −12.050 (14.664) 0.4205 0.4166 −0.076 (0.103) 0.4693 0.380 (0.634) 0.5558 0.2528
Ventilator −2.603 (3.070) 0.4034 8.671 (6.312) 0.1840 0.0602 −0.029 (0.105) 0.7821 −0.224 (0.270) 0.4264 0.5208
DT (msec) in Group 1 DT (msec) in Group 2
p-Value *
Dtslope (m/s2) in Group 1 Dtslope (m/s2) in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker 5.760 (11.040) 0.6055 −0.085 (15.000) 0.9955 0.9809 0.217 (0.754) 0.7748 0.401 (1.13) 0.7260 0.7318
ACE
inhibitor 7.043 (7.366) 0.3459 5.351 (21.630) 0.8070 0.9029 −0.405 (0.504) 0.4275 −1.493 (1.670) 0.3838 0.8565
Diuretic −6.826 (7.220) 0.3515 19.768 (18.900) 0.3075 0.3474 −0.027 (0.509) 0.9587 −0.175 (1.250) 0.8910 0.8608
Aspirin −12.450 (6.540) 0.0659 0.072 (13.060) 0.9956 0.3720 0.081 (0.500) 0.8724 0.984 (0.970) 0.3222 0.4438
Inotropic −14.900 (6.500) 0.0285 31.220 (29.582) 0.3032 0.1105 0.172 (0.489) 0.7274 −0.893 (2.060) 0.6692 0.6133
Ventilator −5.863 (7.190) 0.4209 15.510 (12.320) 0.2219 0.1295 −0.494 (0.488) 0.3196 −0.511 (0.870) 0.5647 0.8518
Sep E’ (cm/s) in Group 1 Sep E’ (cm/s) in Group 2
p-Value *
Sep A’ (cm/s) in Group 1 Sep A’ (cm/s) in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker −0.214 (0.630) 0.7380 −0.339 (1.040) 0.7496 0.8386 −0.274 (0.640) 0.671 0.413 (0.589) 0.4906 0.5893
ACE
inhibitor −0.444 (0.400) 0.2838 0.443 (1.308) 0.7384 0.4364 −0.010 (0.432) 0.9819 1.580 (0.737) 0.0439 0.0692
Diuretic 0.569 (0.401) 0.1649 0.881 (1.480) 0.5579 0.9368 −0.118 (0.421) 0.7812 −1.271 (0.760) 0.1099 0.2247
Aspirin 0.559 (0.379) 0.1503 −0.807 (0.892) 0.3762 0.0976 −0.133 (0.389) 0.7352 0.157 (0.528) 0.7694 0.9436
Inotropic −0.069 (0.390) 0.8634 3.295 (1.509) 0.0405 0.0172 −0.067 (0.397) 0.8667 2.192 (0.963) 0.0335 0.0595
Ventilator −0.153 (0.400) 0.7049 0.626 (0.857) 0.4733 0.5496 −0.026 (0.407) 0.9500 −0.042 (0.490) 0.9334 0.7168
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Sep S’ (cm/s) in Group 1 Sep S’ (cm/s) in Group 2
p-Value *
Sep E/E’ in Group 1 Sep E/E’ in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker 0.709 (0.523) 0.1841 0.315 (0.737) 0.6736 0.6996 0.984 (0.849) 0.2545 0.578 (1.780) 0.7486 0.5182
ACE
inhibitor 0.222 (0.364) 0.5463 −2.146 (1.17) 0.0824 0.0128 0.611 (0.595) 0.3126 −0.924 (2.180) 0.6767 0.4498
Diuretic 0.658 (0.329) 0.0538 0.621 (0.627) 0.3333 0.9380 −0.836 (0.579) 0.1579 −6.780 (2.101) 0.004 0.3941
Aspirin −0.334 (0.330) 0.3228 1.025 (0.536) 0.0696 0.2263 −0.892 (0.560) 0.1225 0.963 (1.537) 0.5378 0.2673
Inotropic −0.423 (0.320) 0.2075 0.988 (1.875) 0.6040 0.3102 −0.604 (0.590) 0.3156 −3.008 (2.690) 0.2768 0.3497
Ventilator 0.018 (0.356) 0.9591 0.452 (0.639) 0.4868 0.3152 −0.273 (0.590) 0.6472 1.803 (1.471) 0.2339 0.0557
Lat E’ (cm/s) in Group 1 Lat E’ (cm/s) in Group 2
p-Value *
Lat A’ (cm/s) in Group 1 Lat A’ (cm/s) in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker 0.405 (1.240) 0.7465 1.465 (1.809) 0.4287 0.8387 0.572 (0.646) 0.3831 2.648 (1.345) 0.0655 0.2615
ACE
inhibitor −0.747 (0.850) 0.3891 1.678 (1.531) 0.2876 0.1776 −0.028 (0.445) 0.9505 0.514 (1.193) 0.6718 0.7572
Diuretic −0.552 (0.860) 0.5285 1.020 (2.413) 0.6774 0.2243 −0.369 (0.443) 0.4124 −0.839 (1.290) 0.5251 0.2938
Aspirin 0.022 (0.888) 0.9808 −0.915 (1.528) 0.5568 0.9290 −0.033 (0.941) 0.9407 0.777 (1.018) 0.4554 0.6567
Inotropic −0.933 (0.850) 0.285 3.028 (1.789) 0.1077 0.0797 0.416 (0.447) 0.3597 3.368 (1.324) 0.0210 0.0533
Ventilator −0.413 (0.860) 0.6359 0.071 (1.340) 0.9585 0.8334 0.166 (0.439) 0.6778 −0.223 (0.260) 0.4023 0.3666
Lat S’ (cm/s) in Group 1 Lat S’ (cm/s) in Group 2
p-Value *
Lat E/E’ in Group 1 Lat E/E’ in Group 2
p-Value *
B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value B (S.E) p-Value
Beta-blocker −0.466 (0.967) 0.6335 −1.440 (1.313) 0.2881 0.6480
ACE
inhibitor 0.681 (0.646) 0.3006 −2.751 (1.070) 0.0205 0.009
Diuretic 0.284 (0.692) 0.6841 −1.581 (1.500) 0.3090 0.0884
Aspirin 2.906 (1.155) 0.0258 0.069 (0.687) 0.9204 0.899 (1.124) 0.4350 0.4729
Inotropic 0.504 (0.472) 0.2973 −4.103 (1.982) 0.0589 0.0495 0.229 (0.689) 0.7418 −3.390 (1.673) 0.0779 0.0756
Ventilator 1.152 (0.324) 0.0017 −0.447 (1.455) 0.7636 0.6628 0.096 (0.691) 0.8900 0.731 (0.981) 0.4666 0.5588
S.E: standard error, ACE inhibitor: angiotensin-converting enzyme inhibitors, IVSd: interventricular septal end diastole, IVSs: interventricular septal end systole, LVIDd: left ventricular
internal diameter end diastole, LVIDs: left ventricular internal diameter end systole, LVPWd: left ventricular posterior wall end diastole, LVPWs: left ventricular posterior wall end systole,
EDV: end-diastolic volume, ESV: end-systolic volume, EF: ejection fraction, SV: stroke volume, FS: fractional shortening, DT: deceleration time, E: peak early inflow velocity, A: peak late
inflow velocity, E’: peak early diastolic velocity, A’: peak late diastolic velocity, S’: peak systolic velocity. p-value *; comparison between two groups’ change values of echocardiographic
data according to cardiac medications or respiratory care.
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Figure 2. The effect of ACE inhibitor and inotropic agents on echocardiographic measurements in each
group. IVSd: Interventricular septal end diastole; IVSs: Interventricular septal end systole, LVIDd:
Left ventricular internal diameter end diastole; LVIDs: Left ventricular internal diameter end systole;
LVPWd: Left ventricular posterior wall end diastole; LVPWs: Left ventricular posterior wall end
systole; EDV: End-diastolic volume; ESV: End-systolic volume; EF: Ejection fraction; SV: Stroke volume;
FS: Fractional shortening; DT: Deceleration time; E: peak early inflow velocity; A: peak late inflow
velocity; E’: peak early diastolic velocity; A’: peak late diastolic velocity; S’: peak systolic velocity;
*: p-value < 0.05.
4. Discussion
DMD is an inherited X-linked disease with a 1/3000 male birth incidence. The disease follows
a predictable clinical course marke by progressive skeletal muscle weak ess. Death occurs in early
adulthood secondary to respiratory or cardiac failure [16]. Cardiac involvement begins as minor
electrocardiographic abnormalities and evolves toward cardiomyopathy with dilatation of the cardiac
chambers and depressed LV EF due to widespread fibrosis; it accounts for up to 40% of deaths [17].
Cardiac management has been challenging because the New York Heart Association classification of
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heart failure relies on reduced exercise tolerance, a feature that in DMD arises from skeletal muscle
and cardiac disease combined. In DMD children, the signs and symptoms of heart failure in the
non-ambulatory individual are frequently subtle and overlooked. The patients with lower LV EF did
not always demonstrate definite symptoms or signs of heart failure with chronic adjustment. Relatively,
they had been in subtle difficulty with chest tightness, discomfort, or tachypnea. As DMD children
might have been adjusted to their gradual progress of cardiac dysfunction, their clinical presentation
of heart failure is probably masked or unusual compared with other patients with heart failure.
Once or twice per year, they were regularly hospitalized for checking the spontaneous respiration or
assisted ventilation with CO2 status, in addition to cardiac functional evaluation by echocardiography.
For the patients with EF < 50%, we added low dosage of oral inotropic agents by combination of
dopamine with dobutamine for stabilizing the vital sign of blood pressure and heart rate for optimal
circulation. Among the enrolled patients, nobody was related implantable cardioverter defibrillator
(ICD) or pacemaker implantation. Perhaps a proactive strategy of early diagnosis and treatment for
cardiomyopathy in DMD is essential to maximize duration and quality of life [18].
In this study, we can notice that all the echocardiographic measurements demonstrated alteration
over time even with or without statistical significances (Table 2). Myocardial wall thickness of IVSd,
IVSs and LVPWd became thinner, systolic functional measurement of EF and FS decreased with
ongoing cardiac dysfunction in DMD patients with aging (Table 2). We investigated to find the relation
between cardiac medications and all the change values of echocardiographic parameters, and revealed
the relationship (Table 3). Interventricular septal thickness at diastole implies the relaxation status of
the radial direction of myofibril from both left ventricle (LV) and right ventricle (RV). While heart failure
proceeds in DMD cardiomyopathy, myocardial thinning might develop at the interventricular septum,
then each free wall of LV and RV in order. As diuretic is one of the medical treatment regimens for heart
failure, for ongoing heart failure status in DMD children, the initial treatment protocol should include
diuretics, ACE inhibitor, and inotropic agents, which helped the myocardial protection. However,
beta-blocker was not contributed to maintain cardiac function.
Moreover, we divided patients into two group based on EF which represents systolic function
(Table 4) [19]. In Group 1, EF decreased by 3.615% annually, while in Group 2, EF decreased by 0.582%
in similar respiratory assist situation (p < 0.05). The difference should be elucidated why the lower
LV EF group demonstrated better preservation of cardiac function. In Table 5, it is noticeable that
Group 2 patients take more numbers of medications (p = 0.001), especially including inotropic agents
for stabilizing their blood pressure and heart rate at 88.9% in Group 2 (p = 0.0009).
It is well known that ACE inhibitor and beta-blocker are helpful for the treatment of heart
failure. Furthermore, ACE inhibitor is recognized to decrease mortality in 10-year follow-up [20].
Similarly, in our study, there was significant positive correlation between ACE inhibitor and the
echocardiographic parameters (Table 6). As Figure 2 demonstrated, especially in Group 2, by taking
ACE inhibitor, IVSs, IVSd and LVPWd were more preserved and improved systolic and diastolic
myocardial function of the measurement of Sep S’, Lat E/E’. In addition, taking inotropic agents showed
statistical significance within similar reasonable ranges of Sep E’, Lat A’, DT, Lat S’, which implied
diastolic and systolic functional preservation. While ACE inhibitor helped to protect myocardial wall
thickness from thinning, but, diminished myocardial wall movement, inotropic agents effected to
enhance systolic myocardial wall velocities by tissue Doppler measurements (Figure 1). Accordingly,
ACE inhibitor with inotropic agents would benefit for cardiac functional preservation, especially in
patients with lower LV EF.
In contrast, taking beta-blocker in Group 2 seemed to be associated deterioration of systolic
function (EF, SV, EDV and FS). Based on this result, we could not expect favorable outcome with
taking beta-blocker in patients with low EF. Despite, it is opposite result of conventional treatment,
further research on this aspect should be necessary in the future.
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LV EF is the most popular cardiac functional prognostic measurement in DMD; however,
recent studies pointed out its low sensitivity to detect early cardiac involvement [11]. In addition,
it is not common to use inotropic agents in DMD children whose EF is maintained within normal
range. Goudot et al. reported that DMD patients without the presence of inotropic reserve (defined as
an increase in LV EF >10% during dobutamine infusion) showed more significant decline of LV EF
than DMD patients with the presence of inotropic reserve (p = 0.031 for difference in trend between
groups). Moreover, they also reported an assessment of inotropic reserve may offer a sensitive
approach for progression of cardiovascular disease in DMD children patients [17]. Based on inotropic
reserve, to investigate the effect of inotropics on cardiac function in DMD cardiomyopathy, would be
helpful to provide a better guideline for the treatment of DMD children. In this study, various medical
treatment including inotropic agents revealed to benefit, not only for the stable blood pressure and heart
rate, but also for preservation of myocardial function with ongoing heart failure in DMD children’s
cardiomyopathy. Inotropic agents demonstrated to help to augmentation of Sep E’, Sep A’ and Lat S’
velocities in patients with LV EF < 45% (Table 5), which implied to sustain myocardial velocities.
The limitation of this study is that this is a single-center retrospective study and the numbers of
patients was relatively small due to DMD disease’s rarity. We did not investigate the steroid treatment
in this study [21]. The eplerenone, a new medication which is reported mineralocorticoid receptor
antagonists in heart failure with preserved ejection fraction (HFpEF), we should investigate the effect
for the DMD cardiomyopathy in the future [8].
Observation for the relationship between medications and echocardiographic parameters in this
study was relatively short-term follow up for complete explanation. Further long-term research should
be preceded for the fruitful results.
5. Conclusions
This study is very important for the cardiomyopathy in DMD children to preserve their myocardial
function with medical treatment including ACE inhibitors, beta-blocker, diuretics, and inotropic agents.
Especially for the patients with lower LV EF, ACE inhibitors with inotropic agent combination therapy
might be beneficial to preserve cardiac function. Further research should be needed for beta-blocker
and diuretics.
We suggest it is supportive to take delicate individualized combination therapy including ACE
inhibitor and inotropic agents for cardiomyopathy in DMD patients with EF < 45%, rather than usual
heart failure therapy.
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